Lipigon Pharmaceuticals AB (publ) reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was SEK 16.05 million. Revenue was SEK 16.1 million compared to SEK 0.093 million a year ago. Net income was SEK 7.13 million compared to net loss of SEK 12.65 million a year ago. Basic earnings per share from continuing operations was SEK 0.11 compared to basic loss per share from continuing operations of SEK 1.3 a year ago. Diluted earnings per share from continuing operations was SEK 0.04.
For the six months, sales was SEK 16.05 million. Revenue was SEK 16.13 million compared to SEK 0.275 million a year ago. Net income was SEK 0.297 million compared to net loss of SEK 21.67 million a year ago. Basic earnings per share from continuing operations was SEK 0.01 compared to basic loss per share from continuing operations of SEK 2.23 a year ago.